• Skip to primary navigation
  • Skip to main content
  • Skip to primary sidebar
  • Skip to footer

MassDevice

The Medical Device Business Journal — Medical Device News & Articles | MassDevice

  • Special Reports
  • Technologies
    • Artificial Intelligence (AI)
    • Cardiovascular
    • Orthopedics
    • Neurological
    • Diabetes
    • Surgical Robotics
  • Business & Finance
    • Wall Street Beat
    • Earnings Reports
    • Funding Roundup
    • Mergers & Acquisitions
    • Initial Public Offering (IPO)
    • Legal News
    • Personnel Moves
    • Medtech 100 Stock Index
  • Regulatory
    • Food & Drug Administration (FDA)
    • Recalls
    • 510(k)
    • Pre-Market Approval (PMA)
    • MDSAP
    • Clinical Trials
  • Resources
    • About MassDevice
    • Leadership in Medtech
    • Manufacturers & Suppliers Search
    • MedTech100 Index
    • Videos
    • Webinars
    • Whitepapers
    • Voices
    • In-Depth Coverage
    • Latest News
  • Attend DeviceTalks
    • Events
      • DeviceTalks Minnesota – May 4
      • DeviceTalks Boston – May 27–28
      • DeviceTalks West
      • DeviceTalks Tuesdays
    • DeviceTalks Podcast Network
      • DeviceTalks Weekly
      • AbbottTalks
      • Boston ScientificTalks
      • DeviceTalks AI
      • IntuitiveTalks
      • MedtechWOMEN Talks
      • MedtronicTalks
      • Neuro Innovation Talks
      • Ortho Innovation Talks
      • Structural Heart Talks
      • StrykerTalks
  • Advertise
  • Subscribe
Home » Recall of Abbott HeartMate comms system is Class I

Recall of Abbott HeartMate comms system is Class I

March 12, 2024 By Sean Whooley

Abbott HeartMate 3 LVAD
The HeartMate 3 LVAD. [Image courtesy of Abbott]
The FDA deemed a recall of the Abbott  (NYSE: ABT) HeartMate Touch Communication System Class I, the most serious kind of recall.

Abbott warned of the potential for its HeartMate Touch System to unexpectedly stop or start. This recall is a correction, not a product removal, according to the FDA. The company reported eight injuries and zero deaths related to this recall.

In total, the recall affects 1,560 devices in the U.S. distributed between May 7, 2020, and Dec. 18, 2023. Abbott initiated the recall on Jan. 3, 2024.

The HeartMate Touch Communication system monitors patients who have an implantable HeartMate 3 left ventricular assist device (LVAD). Abbott has previously reported that HeartMate 3 can extend the lives of advanced heart failure patients by at least five years.

HeartMate’s communications system works with a controller and includes a tablet, wireless adapter, flash drive, power adapter and USB. Only clinicians in hospitals or clinics use the system to provide a detailed display of cardiovascular status. They can use it during implant procedures or whenever they need to closely monitor patients.

The company initiated its recall because issues can occur if the Touch System disconnects from the controller while running a “pump stop” command. When HeartMate Touch reconnects to the same or a new controller, depending on the status of the pump once connected, it will either stop or start.

If stopped at reconnection, the pump restarts. If running, a pump stop occurs, Abbott said. No alarms or indications exist to warn the user that the “pump stop” command still sits in the command queue. Using the affected system may lead to serious adverse health consequences. That includes lightheadedness, sudden change in blood flow, loss of consciousness and death.

Abbott instructed users to follow the instructions for use when performing the “stop pump” sequence. Users should not disconnect their controller white cables or wireless adapter from the power module until the “stop pump” sequence screen with the red progress bar is no longer visible and the “stop pump” screen changes automatically. Additionally, they should not disconnect the pump during priming until the timer reaches zero, the pump stops and a “priming is complete” message appears.

Filed Under: Cardiac Implants, Cardiovascular, Featured, Food & Drug Administration (FDA), Recalls, Regulatory/Compliance, Structural Heart Tagged With: Abbott, FDA

More recent news

  • Siemens Healthineers debuts Accela single-breath radiotherapy system
  • GE HealthCare hires chief AI officer from Medtronic
  • Former Teleflex CEO to lead Inspire competitor Nyxoah
  • Retired Stryker leader Tim Scannell dies at 62
  • HighLife raises more than $90M to advance its TMVR system

About Sean Whooley

Sean Whooley is a senior editor who mainly produces work for MassDevice, Medical Design & Outsourcing and Drug Delivery Business News. He received a bachelor's degree in multiplatform journalism from the University of Maryland, College Park. You can connect with him on LinkedIn or email him at [email protected].

Primary Sidebar

Cart

“md
EXPAND YOUR KNOWLEDGE AND STAY CONNECTED
Get the latest med device regulatory, business and technology news.

DeviceTalks Weekly

See More >
MDO ad
MDO ad

Footer

MASSDEVICE MEDICAL NETWORK

DeviceTalks
Drug Delivery Business News
Medical Design & Outsourcing
Medical Tubing + Extrusion
Drug Discovery & Development
Pharmaceutical Processing World
MedTech 100 Index
R&D World
Medical Design Sourcing

DeviceTalks Webinars, Podcasts, & Discussions

Attend our Monthly Webinars
Listen to our Weekly Podcasts
Join our DeviceTalks Tuesdays Discussion

MASSDEVICE

Subscribe to MassDevice E-Newsletter
Advertise with us
About
Contact us

Copyright © 2026 · Arrowfly LLC and its licensors. All rights reserved.
The material on this site may not be reproduced, distributed, transmitted, cached or otherwise used, except with the prior written permission of Arrowfly.

Privacy Policy